STAT

APRIL 10, 2024

The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.

Vaccines 363

Vaccines Immunity Immunization Drug Development 363

STAT

MARCH 28, 2024

Today, we’re reading about the world’s costliest drug, plus we learn about immune senescence and a potential cause for a kidney autoimmune disease. Sign up to get it in your inbox here. It’s Meghana. Read the rest…

Immunity 264

Immunity Immunization Drug Pricing Drug Development 264

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

JUNE 15, 2022

The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. Improve your drug development rationale across all lines of NSCLC and address challenges when moving therapies forward. Progress sequencing and combination approaches.

Drug Development 106

Drug Development Immunity Immunization 106

BioPharma Dive

AUGUST 22, 2023

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Immunity 98

Immunity Immunization Drug Development 98

World Pharma News

MAY 23, 2023

Jude Children’s Research Hospital and the University of Texas Southwestern Medical Center studied the structure and function of a transporter involved in cancer and immunity. The findings, published in Cell, have implications for drug development.

Drug Development 74

Drug Development Immunity Immunization Hospitals 74

BioPharma Dive

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development 53

Drug Development Immunity Immunization 53

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Drug Development 133

Drug Development Immunity Immunization Vaccines 133

STAT

NOVEMBER 28, 2023

The negative study, called ADVANCE-SC, was the second of two clinical trials involving the Argenx drug called efgartigimod in patients with primary immune thrombocytopenia (ITP), a debilitating condition that destroys blood-clotting platelets. Argenx shares were down 12% in early trading.

Immunity 285

Immunity Immunization Drug Development 285

STAT

SEPTEMBER 26, 2023

Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.

Immunity 334

Immunity Immunization Drug Development 334

STAT

DECEMBER 22, 2022

Sepsis, a deadly overreaction of the immune system to infection, has befuddled clinicians and researchers for decades. Covid-19 made things worse.

Immunity 332

Immunity Immunization Drug Development 332

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunity Immunization 98

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Register for your FREE ticket here: [link].

Drug Development 52

Drug Development Immunity Immunization 52

Pharmaceutical Technology

APRIL 5, 2023

Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development. Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses.

Drug Development 52

Drug Development Immunity Immunization 52

pharmaphorum

MARCH 10, 2022

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms. The post Welcome to the 2nd Chronic HBV Drug Development Summit appeared first on.

Drug Development 52

Drug Development Immunity Immunization Vaccines 52

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immunity 115

Immunity Immunization Drug Development 115

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. It also bodes well for improving clinical trial success rates.

Immunity 135

Immunity Immunization Drug Development 135

pharmaphorum

APRIL 20, 2021

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. The post Non-Small Cell Lung Cancer Drug Development Summit appeared first on. View the event guide now for more details!

Drug Development 52

Drug Development Medical Schools Immunity Immunization 52

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunity 105

Immunity Immunization Drug Development 105

pharmaphorum

APRIL 12, 2021

This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunity 52

Immunity Immunization Drug Development 52

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Immunity 80

Immunity Immunization Hospitals Drug Development 80

pharmaphorum

OCTOBER 6, 2022

As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissues form the tumour micro-environment (TME).

Immunity 52

Immunity Immunization Drug Development 52

European Pharmaceutical Review

AUGUST 9, 2023

As a highly selective BTK inhibitor, remibrutinib “has the potential to be a first-in-class, oral treatment for people living with CSU whose symptoms are refractory despite use of antihistamines,” stated Dr Shreeram Aradhye, President of Global Drug Development and Chief Medical Officer at Novartis.

Immunity 73

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 73

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

Drug Development 52

Drug Development Immunity Immunization Hospitals 52

Pharmaceutical Technology

MAY 19, 2023

OR502 is the company’s additional pipeline candidate anti-LILRB2 antibody and has been designed for rescuing innate as well as adaptive immune responses from LILRB2-mediated immune suppression. It is currently being assessed in a Phase I clinical trial and has entered cohort expansion trials in several cancer indications. ”

Immunity 52

Immunity Immunization Drug Development 52

pharmaphorum

NOVEMBER 11, 2022

Pick the brains of 140+ senior level drug developers across industry and academia at the physical return of the only meeting dedicated to overcoming challenges in biomarker understanding, disease selection and clinical translation in inflammasome-centered drug development.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. 7 Studies also sought to modify oncolytic viruses with additional genes that more efficiently recruit the patient’s immune system to target tumour cells. suppressing activity.

Immunity 101

Immunity Immunization Chemotherapy Packaging 101

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). The acceptance of the IND application for SM17 not only accelerated the company’s clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. “It

Immunity 109

Immunity Immunization Drug Development 109

pharmaphorum

SEPTEMBER 2, 2021

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Syntem’s recently disclosed proprietary small molecule ‘covalent immune recruiting’ (CIR) technology that can enhance recognition of various pathologies by the host immune system.

Immunity 52

Immunity Immunization Vaccines Drug Development 52

Pharmaceutical Technology

JUNE 5, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunity 52

Immunity Immunization Vaccines Drug Development 52

European Pharmaceutical Review

MARCH 11, 2024

For example, broadly neutralising antibodies (bNAbs), capsid inhibitors and maturation inhibitors all might play a role in fighting HIV from the initial binding and fusion of HIV into immune cells, to where it integrates into the cell, out to its assembly and maturation.

Immunity 93

Immunity Immunization Clinical Pharmacology Drug Development 93

pharmaphorum

DECEMBER 8, 2021

A study by the African Health Research Institute (AHRI) has found that the less of immune protection was “extensive but incomplete,” meaning that some level of immunity was retained against the vaccine.

Vaccines 98

Vaccines Immunity Immunization Drug Development 98

Pharmaceutical Business Review

AUGUST 28, 2023

We are excited to leverage our expertise and resources to help develop next-generation booster vaccines that will enhance global immunity and save lives. The post Allucent to expedite Covid-19 booster vaccines development appeared first on Pharmaceutical Business review.

Vaccines 52

Vaccines Clinical Pharmacology Immunity Immunization 52

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Nigel Blackburn, director of cancer research UK’s Centre for Drug Development, said in a statement.

Immunity 65

Immunity Immunization Vaccines Drug Development 65

pharmaphorum

JULY 11, 2022

AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer’s disease candidate AL003, which aims to tackle the neurodegenerative disease by restoring reduced immune system activity in the brain.

Immunity 52

Immunity Immunization Drug Development 52

European Pharmaceutical Review

DECEMBER 28, 2023

As well as presenting recent findings from the pivotal AFM13-104 study, Andreas also reflects on the challenges encountered and conquered in developing Affimed’s innate cell engager, Acimtamig, which targets CD30 on lymphoma cells and CD16A on NK cells. How has the treatment landscape for lymphoma evolved over the past few years?

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

Pharmaceutical Technology

MARCH 4, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunity 40

Immunity Immunization Drug Development 40